Peter Fernandes
Chairman at The Pulmonary Vascular Research Institute
Net worth: 1 906 $ as of 2024-04-29
Peter Fernandes active positions
Companies | Position | Start | End |
---|---|---|---|
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Chairman | - | - |
Career history of Peter Fernandes
Former positions of Peter Fernandes
Companies | Position | Start | End |
---|---|---|---|
BELLEROPHON THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 2023-05-04 | 2023-11-14 |
Chief Executive Officer | 2021-11-10 | 2023-11-14 | |
Director of Finance/CFO | 2023-05-04 | 2023-11-14 | |
General Counsel | 2015-05-19 | 2023-11-14 | |
IKARIA, INC. | General Counsel | 2012-09-30 | 2015-04-30 |
OPTINOSE, INC. | General Counsel | 2010-09-30 | 2012-08-31 |
Novartis Pharmaceuticals AG | Corporate Officer/Principal | 2007-10-31 | 2010-09-30 |
ALTANA Pharma US, Inc.
ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | General Counsel | 2005-01-31 | 2007-09-30 |
Training of Peter Fernandes
The Grant Government Medical College | Graduate Degree |
Principal K. M. Kundnani College of Pharmacy | Undergraduate Degree |
Statistics
International
United States | 6 |
India | 3 |
United Kingdom | 2 |
Operational
General Counsel | 4 |
Comptroller/Controller/Auditor | 1 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
BELLEROPHON THERAPEUTICS, INC. | Health Technology |
OPTINOSE, INC. | Health Technology |
Private companies | 4 |
---|---|
Ikaria, Inc.
Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
ALTANA Pharma US, Inc.
ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | Health Technology |
Novartis Pharmaceuticals AG | |
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Commercial Services |
- Stock Market
- Insiders
- Peter Fernandes
- Experience